⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for tisagenlecleucel

Every month we try and update this database with for tisagenlecleucel cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesNCT02529813
Acute Biphenoty...
Acute Lymphobla...
Blasts 5 Percen...
CD19 Positive
Minimal Residua...
Non-Hodgkin Lym...
Small Lymphocyt...
Stage III Chron...
Stage IV Chroni...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Tisagenlecleuce...
1 Year - 80 YearsM.D. Anderson Cancer Center
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsNCT03876769
B-Cell Acute Ly...
CTL019
1 Year - 25 YearsNovartis
Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell LymphomaNCT04234061
Mantle Cell Lym...
ibrutinib and T...
18 Years - Peter MacCallum Cancer Centre, Australia
Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic LeukemiaNCT03628053
Acute Lymphobla...
Tisagenlecleuce...
Blinatumomab
Inotuzumab
18 Years - Novartis
CTL019 Out of Specification MAP for ALL or DLBCL PatientsNCT03601442
Acute Lymphobla...
Diffuse Large B...
CTL019
1 Day - 25 YearsNovartis
Effectiveness and Safety of Tisagenlecleucel Therapy in Brazilian Patients With B-lymphocyte MalignanciesNCT05541341
Diffuse Large B...
Acute Lymphobla...
Follicular Lymp...
tisagenlecleuce...
- 100 YearsNovartis
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid MalignanciesNCT02529813
Acute Biphenoty...
Acute Lymphobla...
Blasts 5 Percen...
CD19 Positive
Minimal Residua...
Non-Hodgkin Lym...
Small Lymphocyt...
Stage III Chron...
Stage IV Chroni...
Cyclophosphamid...
Fludarabine Pho...
Laboratory Biom...
Tisagenlecleuce...
1 Year - 80 YearsM.D. Anderson Cancer Center
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaNCT05633615
Diffuse Large B...
Grade 3b Follic...
Primary Mediast...
Recurrent Diffu...
Refractory Diff...
Transformed Fol...
Transformed Mar...
Axicabtagene Ci...
Biospecimen Col...
Computed Tomogr...
Cyclophosphamid...
Fludarabine
Lisocabtagene M...
Mosunetuzumab
Patient Observa...
Polatuzumab Ved...
Positron Emissi...
Tisagenlecleuce...
18 Years - SWOG Cancer Research Network
Comparison of Clinical Outcomes Among Patients Treated With TisagenlecleucelNCT05541328
Diffuse Large B...
Tisagenlecleuce...
18 Years - 99 YearsNovartis
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyNCT04890236
Recurrent Diffu...
Refractory Diff...
Duvelisib
Tisagenlecleuce...
18 Years - Emory University
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive PatientsNCT03876769
B-Cell Acute Ly...
CTL019
1 Year - 25 YearsNovartis
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyNCT05075603
Refractory Diff...
Refractory Diff...
Recurrent Diffu...
Refractory High...
Refractory Tran...
Efineptakin alf...
Tisagenlecleuce...
Axicabtagene ci...
Lisocabtagene M...
18 Years - NeoImmuneTech
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS StudyNCT04890236
Recurrent Diffu...
Refractory Diff...
Duvelisib
Tisagenlecleuce...
18 Years - Emory University
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell TherapyNCT05075603
Refractory Diff...
Refractory Diff...
Recurrent Diffu...
Refractory High...
Refractory Tran...
Efineptakin alf...
Tisagenlecleuce...
Axicabtagene ci...
Lisocabtagene M...
18 Years - NeoImmuneTech
Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular LymphomaNCT03568461
Follicular Lymp...
tisagenlecleuce...
18 Years - Novartis
CTL019 Out of Specification MAP for ALL or DLBCL PatientsNCT03601442
Acute Lymphobla...
Diffuse Large B...
CTL019
1 Day - 25 YearsNovartis
Comparison of Clinical Outcomes Among Patients Treated With TisagenlecleucelNCT05541328
Diffuse Large B...
Tisagenlecleuce...
18 Years - 99 YearsNovartis
Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin LymphomaNCT03570892
Non-Hodgkin Lym...
Tisagenlecleuce...
Platinum-based ...
18 Years - Novartis
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell MalignanciesNCT06408194
Leukemia
Acute Lymphobla...
CD22CART infusi...
Tisagenlecleuce...
1 Year - 25 YearsStanford University
Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)NCT04225676
Acute Lymphobla...
Tisagenlecleuce...
2 Years - 25 YearsNovartis
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: